Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Heart Failure V: Medical Management

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...

Heart Failure VI: Adjunct Therapies

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...

Heart Failure Drugs: β-Blockers

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...

Heart Failure Drugs: Diuretics

Heart Failure Drugs: Diuretics

Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...

Heart Failure Drugs: Inotropic Agents

Heart Failure Drugs: Inotropic Agents

Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Hepatic transaminase and alkaline phosphatase enzyme levels in HIV/HBV co-infected and HIV mono-infected patients in Maiduguri, Nigeria.

Nigerian journal of clinical practice·2013

Same author

Perry syndrome: a disorder to consider in the differential diagnosis of Parkinsonism.

Journal of the neurological sciences·2013

Same author

Passage of an iron bar through the head: 50-year follow-up.

Journal of neurology·2011

Same author

Serum C-reactive protein in Nigerians with type 2 diabetes mellitus.

Nigerian journal of medicine : journal of the National Association of Resident Doctors of Nigeria·2011

Same author

Serum C-reactive protein in Nigerians with type II diabetes mellitus.

Nigerian quarterly journal of hospital medicine·2010

Same author

Malaria vaccine: the pros and cons.

Nigerian journal of medicine : journal of the National Association of Resident Doctors of Nigeria·2010

Search research articles

Related Experiment Videos

Pharmacotherapy for chronic heart failure.

J A Saleh¹, B M Aji, H Yusuph

¹Dept. Of Medicine, Imperial College, Hammersmith Hospital, London. drjalals@yahoo.com

Nigerian Journal of Medicine : Journal of the National Association of Resident Doctors of Nigeria

|August 19, 2007

Summary

This review supports the use of various medications, including beta-blockers and ACE inhibitors, for managing chronic heart failure. Effective drug therapy aims to stabilize patients, improve symptoms, and enhance long-term survival.

Related Experiment Videos

Area of Science:

Cardiology
Pharmacology

Background:

Heart failure is a chronic, progressive condition where the heart cannot pump enough blood.
Diagnosis can be complex due to varied presentations, from classical to non-specific symptoms.
Management focuses on symptom relief, quality of life, preventing hospitalizations, and prolonging survival.

Purpose of the Study:

To review current pharmacologic and non-pharmacologic management strategies for chronic heart failure.
To identify effective drug classes for improving patient outcomes in heart failure.

Main Methods:

Literature review of medical journals and internet resources.
Utilized keywords: Heart failure, Chronic heart failure, Diuretics, Vasodilators, Angiotensin receptor blockers (ARBS), Angiotensin converting enzyme inhibitors (ACEI).
Consulted resources from the National Heart, Lung and Blood Institute, Canadian Cardiovascular Society, and American College of Cardiology.

Main Results:

The review supports the use of beta-blockers, ACE inhibitors (ACEI), ARBS, digitalis, diuretics, vasodilators, and aldosterone antagonists.
These medications are crucial components in the management of chronic heart failure.

Conclusions:

Drug therapy objectives include short-term stabilization and symptomatic improvement, and long-term goals of limiting disease progression and improving survival.
Establishing the cause and treating aggravating factors are essential.
Medications are often used in combination for maximal therapeutic effect, with potential for add-on therapy based on comorbidities.